Nykode Therapeutics AS (NYKD.OL)
- Previous Close
2.6620 - Open
2.7500 - Bid 2.8000 x --
- Ask 2.8000 x --
- Day's Range
2.6500 - 2.7500 - 52 Week Range
1.5500 - 17.2000 - Volume
405,155 - Avg. Volume
1,438,165 - Market Cap (intraday)
874.49M - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2500 - Earnings Date May 14, 2025
- Forward Dividend & Yield 1.00 (37.34%)
- Ex-Dividend Date May 27, 2025
- 1y Target Est
6.75
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
nykode.comRecent News: NYKD.OL
View MorePerformance Overview: NYKD.OL
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NYKD.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NYKD.OL
View MoreValuation Measures
Market Cap
874.49M
Enterprise Value
-286.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.70
Price/Book (mrq)
0.62
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.70%
Return on Equity (ttm)
-25.25%
Revenue (ttm)
9.16M
Net Income Avi to Common (ttm)
-38.82M
Diluted EPS (ttm)
-1.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
115.4M
Total Debt/Equity (mrq)
2.52%
Levered Free Cash Flow (ttm)
-34.3M